Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$3.23
+7.0%
$2.26
$1.89
$3.68
$963.91M0.363.10 million shs20.08 million shs
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
$3.50
-1.4%
$3.28
$2.71
$4.73
$670.34M1.23965,065 shs471,165 shs
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
$4.03
-2.2%
$3.94
$2.14
$6.82
$172.82M1.2384,696 shs68,588 shs
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$3.25
-6.3%
$3.78
$2.28
$6.71
$412.28M1.631.15 million shs906,189 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
+6.95%+33.47%+56.80%+34.58%-5.83%
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
-1.41%+2.64%+4.48%+5.42%+10.06%
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
-2.18%-4.05%+5.22%-28.92%+54.41%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
-6.34%+13.64%+9.06%-38.10%+20.37%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.5298 of 5 stars
3.41.00.00.02.63.30.6
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
2.2499 of 5 stars
3.50.00.00.03.22.50.6
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
1.3602 of 5 stars
3.51.00.00.02.50.00.0
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
4.6333 of 5 stars
3.33.00.04.34.14.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.75
Moderate Buy$8.33158.00% Upside
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
3.00
Buy$5.5057.14% Upside
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
3.00
Buy$8.0098.51% Upside
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
2.50
Moderate Buy$5.5069.23% Upside

Current Analyst Ratings Breakdown

Latest DMAC, ORGO, ABUS, and ABCL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/16/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $10.00
4/16/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$4.00 ➝ $5.00
3/28/2025
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
3/19/2025
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $10.00
(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$23.11M41.70N/AN/A$3.97 per share0.81
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
$6.40M104.69N/AN/A$0.63 per share5.56
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
N/AN/AN/AN/A$1.35 per shareN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$458.76M0.90$0.21 per share15.72$2.11 per share1.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$146.40M-$0.56N/AN/AN/A-533.32%-15.73%-12.22%8/5/2025 (Estimated)
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
-$72.85M-$0.41N/AN/AN/A-1,137.65%-68.18%-51.55%7/30/2025 (Estimated)
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
-$19.38M-$0.64N/AN/AN/AN/A-43.67%-40.81%8/6/2025 (Estimated)
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$4.95M-$0.17N/AN/AN/A-1.62%-2.69%-1.63%8/6/2025 (Estimated)

Latest DMAC, ORGO, ABUS, and ABCL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million
5/13/2025Q1 2025
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
-$0.18-$0.18N/A-$0.18N/AN/A
5/8/2025Q1 2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.17-$0.15+$0.02-$0.15$7.12 million$4.24 million
5/8/2025Q1 2025
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
3/27/2025Q4 2024
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
-$0.08-$0.07+$0.01-$0.07$2.20 million$1.57 million
3/17/2025Q4 2024
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
-$0.17-$0.18-$0.01-$0.18N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
N/AN/AN/AN/AN/A
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
N/AN/AN/AN/AN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
9.34
9.34
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
N/A
7.02
7.02
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
N/A
11.81
11.81
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
0.21
3.09
2.74

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
43.79%
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
10.12%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
49.57%

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
28.90%
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
20.30%
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
7.30%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
33.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
500298.42 million212.66 millionOptionable
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
90191.53 million181.91 millionOptionable
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
2042.88 million39.68 millionOptionable
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
950126.85 million79.33 millionOptionable

Recent News About These Companies

CMS reviewing coverage policies for skin substitute products

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbCellera Biologics stock logo

AbCellera Biologics NASDAQ:ABCL

$3.23 +0.21 (+6.95%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$3.18 -0.04 (-1.39%)
As of 06:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Arbutus Biopharma stock logo

Arbutus Biopharma NASDAQ:ABUS

$3.50 -0.05 (-1.41%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$3.50 0.00 (0.00%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

DiaMedica Therapeutics stock logo

DiaMedica Therapeutics NASDAQ:DMAC

$4.03 -0.09 (-2.18%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$4.03 0.00 (0.00%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$3.25 -0.22 (-6.34%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$3.19 -0.06 (-1.85%)
As of 06:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.